Prof Thomas Voit, DMD expert, interview with Wilsons advisory, page-12

You reckon the nerds at Big Pharma will be replaying the interview with Professor Voit, over and over?

Here is another recent example of Big Pharma partnering with small players....this is in Gene Therapy space just like Roche and Sarepta deal.

NOTE: this is "pre-clinical" and yet Takeda are paying upfront cash and total $900M if Carmine can produce positive 'proof of concept' studies....we're not even talking P1 here....let alone P2 efficacy data.

Price and Goolsbee need to bring this home using their US 'biobucks' contacts.
___________________


Takeda pens $900M biobucks pact with Carmine for non-viral gene therapy work

The deal could be worth as much as $900 million, with Takeda leading Carmine's convertible note seed plus funding round by extending a $5 million convertible loan to the biotech. There’s an upfront payment and extra research funding cash, though details of dollar amounts here were not given.
Takeda nabs an option to license the programs following the completion of preclinical proof of concept studies; from here, it would be responsible for clinical development and sales.
Carmine Therapeutics was founded last year by Esco Ventures X, a life science fund, professor Harvey Lodish of the Whitehead Institute at MIT and Singaporean professors Minh Le and Jiahai Shi.

https://www.fiercebiotech.com/biotech/takeda-pens-900m-biobucks-pact-carmine-tx-for-non-viral-gene-therapy-work?